SCHEMBL4183852

SCHEMBL4183852

Fc1ccccc1OCCN1CCN(CCCOc2ccc(C(F)(F)F)cc2)CC1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DRD2 P14416 5/20 0.60
DRD3 P35462 2/20 0.60
DRD1 P21728 1/20 0.60
KDM4E B2RXH2 3/20 0.57
LTA4H P09960 3/20 0.57
MEN1 O00255 1/20 0.55
ALDH1A1 P00352 1/20 0.55
CYP1A2 P05177 1/20 0.55
CYP3A4 P08684 1/20 0.55
CYP2D6 P10635 1/20 0.55
CYP2C9 P11712 1/20 0.55
CYP2C19 P33261 1/20 0.55
KMT2A Q03164 1/20 0.55
CACNA1B Q00975 2/20 0.54
L3MBTL1 Q9Y468 1/20 0.54
HTR1A P08908 1/20 0.52
HTR2A P28223 1/20 0.52
HRH1 P35367 1/20 0.52
TMEM97 Q5BJF2 1/20 0.52
SIGMAR1 Q99720 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4182249 0.96 LTA4H (0.61) DRD2DRD3DRD1KDM4ELTA4H
SCHEMBL4185349 0.88 LTA4H (0.55) DRD2DRD3DRD1LTA4HMEN1
SCHEMBL4188794 0.87 LTA4H (0.66) DRD2DRD3DRD1LTA4HMEN1
SCHEMBL4184816 0.87 KDM4E (0.59) DRD2KDM4ELTA4HMEN1ALDH1A1
SCHEMBL4173098 0.84 LTA4H (0.59) DRD2DRD3DRD1KDM4ELTA4H
SCHEMBL4182932 0.83 KDM4E (0.62) DRD2KDM4ELTA4HMEN1ALDH1A1
SCHEMBL4179888 0.83 HRH3 (0.60) DRD2DRD3KDM4EMEN1ALDH1A1
SCHEMBL4184121 0.83 KDM4E (0.52) DRD2DRD3DRD1KDM4ELTA4H
SCHEMBL4174980 0.83 LTA4H (0.71) DRD2DRD3DRD1KDM4ELTA4H
SCHEMBL8232159 0.83 KDM4E (0.79) DRD2DRD3DRD1KDM4EMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090221607-A1 Piperazine Derivatives M'S SCIENCE CORPORATION (JP) 2009-09-03 US claimed
US-20090221607-A1 Piperazine Derivatives M'S SCIENCE CORPORATION (JP) 2009-09-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090221607-A1 Piperazine Derivatives SIGMAR1, OPRL1, OPRK1 DRD2 61/4885DRD3 140/4885DRD1 98/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.